Evidence map›Paper›PMID 21423209›Full record

ArticleOncogene2011

β-Catenin is required for Ron receptor-induced mammary tumorigenesis.

P K Wagh, J K Gray, G M Zinser, J Vasiliauskas, L James, S P Monga, S E Waltz

Open access · greenAbstract read
In one paragraph

Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Article
  3. Small-molecule agents for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

P K WaghDepartment of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0521, USA.
J K Gray
G M Zinser
J Vasiliauskas
L James
S P Monga
S E Waltz
University of Cincinnati Medical Center · USUniversity of Pittsburgh · USVeterans Health Administration · US

Funding

Training Program in Cancer TherapeuticsT32CA117846 · NCI · UNIVERSITY OF CINCINNATI · PI PRICE, CAROLYN M, TAKIAR, VINITA · 2006 to 2022
$6.5M
REGULATION OF CELLULAR GROWTH AND DIFFERENTIATIONT32CA059268 · NCI · UNIVERSITY OF CINCINNATI · PI KHAN, SOHAIB A. · 1993 to 2010
$2.3M
The Ron Receptor in Mammary Gland BiologyR01CA100002 · NCI · UNIVERSITY OF CINCINNATI · PI WALTZ, SUSAN E · 2004 to 2008
$1.5M
Ron Receptor Tyrosine Kinase Signaling in Breast CancerI01BX000803 · VA · CINCINNATI VA MEDICAL CENTER RESEARCH · PI WALTZ, SUSAN E · 2011 to 2025
–
BLRD VA I01 BX000803NCI NIH HHS CA100002NCI NIH HHS R01 CA100002NCI NIH HHS T32 CA059268NCI NIH HHS T32 CA117846
6 · The paper itself

Abstract

Our previous studies demonstrated that selective overexpression of the Ron receptor tyrosine kinase in the murine mammary epithelium leads to mammary tumor formation. Biochemical analysis of mammary tumor lysates showed that Ron overexpression was associated with increases in β-catenin expression and tyrosine phosphorylation. β-Catenin has also been shown to be regulated through tyrosine phosphorylation by the receptor tyrosine kinases Met, Fer and Fyn. However, the molecular and physiological roles of β-catenin and β-catenin tyrosine phosphorylation downstream of Ron are not known. To investigate this association, we show that Ron and β-catenin are coordinately elevated in human breast cancers. Our data also demonstrate that activation of Ron, through ligand binding by hepatocyte growth factor-like protein (HGFL), induces the tyrosine phosphorylation of β-catenin, primarily on tyrosine residues Tyr 654 and Tyr 670. In addition, HGFL-mediated Ron activation induces both β-catenin nuclear localization and transcriptional activity, with Tyr 654 and Tyr 670 residues of β-catenin being critical for these processes. We also demonstrate that a knockdown of Ron in breast cancer cell lines leads to a loss of HGFL-induced β-catenin-dependent transcriptional activation and cell growth, which can be rescued by activation of canonical Wnt/β-catenin signaling. Moreover, we show that HGFL-dependent Ron activation mediates upregulation of the β-catenin target genes cyclin D1 and c-myc, and that expression of these target genes in breast cancer cells is decreased following inhibition of Ron and/or β-catenin. Finally, we show that genetic ablation of β-catenin in Ron-expressing breast cancer cells decreases cellular proliferation in vitro, as well as mammary tumor growth and metastasis, following orthotopic transplantation into the mammary fat pad. Together, our data suggest that β-catenin is a crucial downstream regulator of Ron receptor activation and is an important mediator of mammary tumorigenesis.

Indexed as

AnimalsBase Sequencebeta CateninCell ProliferationDNA PrimersImmunohistochemistryMammary Neoplasms, ExperimentalMicePhosphorylationPolymerase Chain ReactionReceptor Protein-Tyrosine KinasesTyrosinebeta CateninDNA PrimersReceptor Protein-Tyrosine KinasesRON proteinTyrosine

Identifiers

PMID21423209
PMCPMC3134560
OpenAlexW1975837291

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.